QIAGEN N.V. QGEN recently published the outcomes of a multicenter clinical study highlighting the precision of its QIAstat-Dx syndromic testing solution in the diagnosis of the causes of acute gastroenteritis.This has been a major step for the company toward offering accurate diagnosis and treatment of gastroenteritis.Study Results in DetailsThe study proved that the QIAstat-Dx Gastrointestinal Panel was highly sensitive (98.2% positive percent agreement, a measure of ability to detect pathogens) and specific (99.9% negative percent agreement, a measure of ability to identify true negative samples). The panel could successfully identify multiple pathogens in nearly one-third of the patient samples that tested positive.The study also demonstrated the ability of the QIAstat-Dx panel to provide cycle threshold (CT) values and amplification curves. This provides the system an edge in inferring diagnostic findings for gastrointestinal syndromes, which can be distorted by co-infections or false positives in testing. The company noted that other currently-existing syndromic platforms are not equipped to offer these facilities. Introduced in Europe (in early 2018) and the United States (in mid-2019), the QIAstat-Dx system facilitates swift, cost-efficient and easy-to-use syndromic testing with novel Sample to Insight solutions. The QIAstat-Dx Gastrointestinal Panel provides differential diagnosis of more than 20 bacterial, viral and parasitic pathogens resulting in gut infections.Market ProspectsPer Grand View Research, the global gastrointestinal therapeutics market was valued at $51.9 billion in 2016 and is expected to see a CAGR of 6.6% over the forecast period of 2018-2025. Hence, the study results come at an ideal time.Recent DevelopmentsLately, the company has been investing in a few developments pertaining to the QIAstat-Dx system.In May 2019, QIAGEN announced the U.S. launch of the QIAstat-Dx syndromic testing system after attaining 510(k) clearance by the FDA. Specifically, the company launched the multiplex QIAstat-Dx Respiratory Panel for simultaneous qualitative diagnosis and identification of multiple respiratory viral and bacterial pathogens.Price PerformanceIn the past year, the stock has declined 7.6% compared with the broader industry’s fall of 24%.Zacks Rank & Key PicksQIAGEN currently carries a Zacks Rank #4 (Sell).A few better-ranked stocks in the broader medical space are Medtronic MDT, Baxter BAX and NuVasive Corporation NUVA, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Medtronic’s long-term earnings growth rate is expected to be 7.13%.Baxter’s long-term earnings growth rate is projected at 12.8%.NuVasive’s long-term earnings growth rate is expected to be 12.75%.Today's Best Stocks from ZacksWould you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year. See their latest picks free >Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research